Abstract
Adipose tissue (AT) is now widely accepted as a key secretary organ, as well as an energy storage depot. It secretes a series of cytokines, hormones and bioactive molecules: adipokines. Adiponectin is an abundant systemic adipokine that uniquely is reduced in obesity and increases on weight loss, is anti-inflammatory, promotes insulin sensitivity and affords cardiometabolic protection. It was considered a true adipokine, in that it is exclusively generated by the adipocytes of the adipose tissue. However, recent evidence points to it being secreted by a range of other organs. This review summarizes the non-adipose sources of adiponectin especially that derived from the endothelium, its vasoprotective role and intracellular signalling pathways. Endothelium derived adiponectin may potentially be a new target for clinical intervention in cardiovascular disease.
Keywords: Adiponectin, coronary artery bypass grafting, endothelium, perivascular adipose tissue.
Graphical Abstract
Current Vascular Pharmacology
Title:Adiponectin: An Endothelium-Derived Vasoprotective Factor?
Volume: 14 Issue: 2
Author(s): Lei Shen, Ian M. Evans, Domingos Souza, Mats Dreifaldt, Michael R. Dashwood and Mohamed-Ali Vidya
Affiliation:
Keywords: Adiponectin, coronary artery bypass grafting, endothelium, perivascular adipose tissue.
Abstract: Adipose tissue (AT) is now widely accepted as a key secretary organ, as well as an energy storage depot. It secretes a series of cytokines, hormones and bioactive molecules: adipokines. Adiponectin is an abundant systemic adipokine that uniquely is reduced in obesity and increases on weight loss, is anti-inflammatory, promotes insulin sensitivity and affords cardiometabolic protection. It was considered a true adipokine, in that it is exclusively generated by the adipocytes of the adipose tissue. However, recent evidence points to it being secreted by a range of other organs. This review summarizes the non-adipose sources of adiponectin especially that derived from the endothelium, its vasoprotective role and intracellular signalling pathways. Endothelium derived adiponectin may potentially be a new target for clinical intervention in cardiovascular disease.
Export Options
About this article
Cite this article as:
Shen Lei, Evans M. Ian, Souza Domingos, Dreifaldt Mats, Dashwood R. Michael and Vidya Mohamed-Ali, Adiponectin: An Endothelium-Derived Vasoprotective Factor?, Current Vascular Pharmacology 2016; 14 (2) . https://dx.doi.org/10.2174/1570161114666151202210128
DOI https://dx.doi.org/10.2174/1570161114666151202210128 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
General Aspects of Metal Toxicity
Current Medicinal Chemistry Chalcones as Versatile Synthons for the Synthesis of 5- and 6-membered Nitrogen Heterocycles
Current Organic Chemistry Targeting IL-17 and IL-23 in Immune Mediated Renal Disease
Current Medicinal Chemistry Epidemiology and Etiology of Alzheimer’s disease: From Genetic to Non- Genetic Factors
Current Alzheimer Research Editorial: Exploring Lipid-related Treatment Options for the Treatment of NASH
Current Vascular Pharmacology Provocation Tests in Diagnosing Drug Hypersensitivity
Current Pharmaceutical Design Patents and Heart Valve Surgery - II: Tissue Valves
Recent Patents on Cardiovascular Drug Discovery Cerebral Aneurysm Formation in Nitric Oxide Synthase-3 Knockout Mice
Current Neurovascular Research Foreword:
Current Pharmaceutical Design Human Milk has Anti-Oxidant Properties to Protect Premature Infants
Current Pediatric Reviews Assessing Myocardial Metabolism with Hybrid PET Imaging: Instrumentation, Concepts, and Workflows
Current Pharmaceutical Design Lipases as Modulators of Atherosclerosis in Murine Models
Current Drug Targets iMethylK-PseAAC: Improving Accuracy of Lysine Methylation Sites Identification by Incorporating Statistical Moments and Position Relative Features into General PseAAC via Chou’s 5-steps Rule
Current Genomics A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Natural Products as Anti-glycation Agents: Possible Therapeutic Potential for Diabetic Complications
Current Diabetes Reviews Diagnosis of Diabetes in a Diabetic Patients Urine and Blood Using a Combination Electrode with a Ubiquitous Handheld Analyzer
Current Analytical Chemistry Plasminogen Activator Inhibitor-1
Current Medicinal Chemistry Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design Sex Steroid Hormones, Cardiovascular Diseases and The Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Metabolic Enzymes of Helminth Parasites: Potential as Drug Targets
Current Protein & Peptide Science